Enlivex Therapeutics (NASDAQ:ENLV) Stock Rating Lowered by Wall Street Zen

Key Points

• Wall Street Zen downgraded Enlivex Therapeutics (NASDAQ:ENLV) from a "hold" to a "sell" in a recent research note.
• Analyst views are mixed: HC Wainwright raised its target to $13 and gave a "buy," Weiss Ratings reaffirmed a "sell (d-)," and the MarketBeat consensus remains a "Hold" with an average target of $13.00.
• Shares opened at $1.05 and were down about 3.7%, trading near their 12‑month low with a market cap of roughly $249 million, and institutional ownership is low (~1.02%) despite recent purchases by several hedge funds.

Enlivex Therapeutics (NASDAQ:ENLV - Get Free Report) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued on Saturday.

A number of other analysts have also commented on ENLV. HC Wainwright lifted their target price on Enlivex Therapeutics from $7.00 to $13.00 and gave the stock a "buy" rating in a report on Monday, January 12th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Enlivex Therapeutics in a report on Monday, December 29th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $13.00.

Enlivex Therapeutics Stock Down 3.7%

Shares of NASDAQ ENLV opened at $1.05 on Friday. Enlivex Therapeutics has a twelve month low of $0.66 and a twelve month high of $2.10. The firm has a market cap of $249.25 million, a P/E ratio of -1.91 and a beta of 1.55. The company has a 50 day moving average of $1.10 and a 200 day moving average of $1.02.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ENLV. Citizens Financial Group Inc. RI bought a new stake in Enlivex Therapeutics in the 3rd quarter worth approximately $241,000. Renaissance Technologies LLC lifted its holdings in shares of Enlivex Therapeutics by 99.4% during the 4th quarter. Renaissance Technologies LLC now owns 313,628 shares of the company's stock valued at $221,000 after buying an additional 156,336 shares during the period. HRT Financial LP boosted its stake in shares of Enlivex Therapeutics by 719.4% in the 4th quarter. HRT Financial LP now owns 153,990 shares of the company's stock worth $108,000 after buying an additional 135,198 shares during the last quarter. Jane Street Group LLC boosted its stake in shares of Enlivex Therapeutics by 527.4% in the 1st quarter. Jane Street Group LLC now owns 80,759 shares of the company's stock worth $78,000 after buying an additional 67,886 shares during the last quarter. Finally, Invesco Ltd. bought a new stake in shares of Enlivex Therapeutics in the fourth quarter worth $43,000. Institutional investors own 1.02% of the company's stock.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company's lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.